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To enhance the success rate of antiangiogenic therapies in the clinic, it is crucial to identify parameters for tumour angiogenesis that
can predict response to these therapies. In brain tumours, one such parameter is vascular leakage, which is a response to tumour-
derived vascular endothelial growth factor-A and can be measured by Gadolinium-DTPA (Gd-DTPA)-enhanced magnetic resonance
imaging (MRI). However, as vascular permeability and angiogenesis are not strictly coupled, tumour blood volume may be another
potentially important parameter. In this study, contrast-enhanced MR imaging was performed in three orthotopic mouse models for
human brain tumours (angiogenic melanoma metastases and E34 and U87 human glioma xenografts) using both Gd-DTPA to detect
vascular leakage and ultrasmall iron oxide particles (USPIO) to measure blood volume. Pixel-by-pixel maps of the enhancement in the
transverse relaxation rates (DR2 and DR2*) after injection of USPIO provided an index proportional to the blood volume of the
microvasculature and macrovasculature, respectively, for each tumour. The melanoma metastases were characterised by a blood
volume and vessel leakage higher than both glioma xenografts. The U87 glioblastoma xenografts displayed higher permeability and
blood volume in the rim than in the core. The E34 glioma xenografts were characterised by a relatively high blood volume,
accompanied by only a moderate blood–brain barrier disruption. Delineation of the tumour was best assessed on post-USPIO
gradient-echo images. These findings suggest that contrast-enhanced MR imaging using USPIOs and, in particular, DR2 and DR2*
quantitation, provides important additional information about tumour vasculature.
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Growth and metastasis of solid tumours are considered to strictly
depend on angiogenesis (Folkman, 1992). However, especially in
organs with high vessel densities such as lung, liver and brain, the
dependency of infiltrative tumours on angiogenesis is not always
evident because the pre-existent vasculature may supply sufficient
blood to the tumour cells to allow tumour progression. In the
brain, the prototypes of such tumours are the diffuse infiltrative
gliomas. Importantly, co-opted blood vessels in such brain
tumours may be relatively unaffected by the tumour cells and
may retain the highly specialised blood–brain barrier function
(Kusters et al, 2002; Leenders et al, 2003). This probably explains
why diffuse infiltrative parts of glioblastoma multiforma, the most
frequent and most malignant glial brain tumour, as well as low-
grade, infiltrative gliomas do not show enhancement in Gadoli-
nium-DTPA (Gd-DTPA) magnetic resonance imaging (MRI)
(Leenders et al, 2003). Indeed, in brain tumours, Gd-DTPA leaks
from the vascular system into the interstitial space only when
the blood–brain barrier is disrupted, that is, when the tumour
increases the permeability of pre-existing blood vessels or induces
the growth of leaky blood vessels.
The detailed characterisation of tumour vasculature with respect
to permeability and vascular volume provides essential insight into
tumour physiology and is a prerequisite to investigate and evaluate
tumour response to antiangiogenic therapy. Apart from Gd-DTPA,
superparamagnetic ultrasmall iron oxide particles (USPIO)-
enhanced MRI has been demonstrated to be useful for the
characterisation of the tumour vasculature (Dennie et al, 1998;
Su et al, 1998; Le Duc et al, 1999; Tropres et al, 2001; Turetschek
et al, 2001; Kusters et al, 2002; Bremer et al, 2003; Leenders et al,
2003; Pathak et al, 2003; Robinson et al, 2003; van Laarhoven et al,
2006). Although Gd-DTPA is used routinely in the clinic since
many years, USPIOs have only recently been introduced for
human applications (Enochs et al, 1999; Harisinghani et al, 2003).
Superparamagnetic ultrasmall iron oxide particle contrast agents
remain intravascular for a prolonged period of time and drastically
increase the transverse water proton MR relaxation rate, the
USPIO T2 relaxivity being up to 20 times that of Gd-DTPA
(Gambarota et al, 2006). Superparamagnetic ultrasmall iron oxide
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sparticle thus provides a good marker for alterations in blood
volume in different tissues, a characteristic that might be exploited
for tumour detection and characterisation, such as in human brain
(Enochs et al, 1999; Varallyay et al, 2002; Taschner et al, 2005).
Although the USPIO-induced signal dephasing extends beyond the
size of the main magnetic field perturbers, that is, the blood
vessels, this does not seem to confound tumour delineation at the
human scale. Previous studies have already shown that magnetic
susceptibility effects caused by USPIO can be used to assess
relative blood volumes within tumours (Dennie et al, 1998; Le Duc
et al, 1999). In particular, the change in the transverse relaxation
rates DR2 and DR2* after injection of USPIO provides an index
proportional to the blood volume of the microvasculature and
macrovasculature, respectively (Kennan et al, 1994; Weisskoff
et al, 1994). In murine brain tumours, however, so far only
qualitative measurements of the decrease in signal intensity
following USPIO administration have been reported (Leenders
et al, 2003).
We have previously shown that treatment of angiogenic brain
tumours with ZD6474, a tyrosine kinase inhibitor with specificity
towards vascular endothelial growth factor (VEGF) receptor 2 and
the epidermal growth factor receptor, resulted in conversion to a
nonangiogenic phenotype, characterised by perivascular growth
along pre-existent vessels (Leenders et al, 2004). Importantly, this
treatment also resulted in restoration of the blood–brain barrier
and a concomitant inability to detect these tumours with
conventional Gd-DTPA MRI. This restoration of the blood–brain
barrier may thus lead to overestimation of therapeutic efficacy. To
detect infiltratively growing brain tumours, MR-based quantification
of blood volume may have added value in evaluating antiangio-
genic therapies. Indeed, we have previously shown that intra-
cerebral lesions of Mel57, a human melanoma cell line with no
notable expression of VEGF-A, were not detectable in Gd-DTPA
MR images, yet were visible in T2 images after intravenous
injection of USPIOs (Leenders et al, 2003). Similar results have
been obtained with intracerebral U87 xenografts (Claes et al, 2008).
This detection was based on the low intratumoral vascular volume,
relative to the surrounding brain parenchyma.
In the current study, we aimed to develop imaging protocols that
better define the vascular characteristics of different tumours.
Tumour models were used, of which the vasculature has been
extensively characterised at the morphological level. Tumour-
bearing mice were subjected to both Gd-DTPA and USPIO
imaging. Blood volume maps were generated for all tumours, by
calculating DR2 and DR2* following USPIO administration.
MATERIALS AND METHODS
Tumour models
E34 is a transplantable human glioblastoma xenograft line that is
maintained as subcutaneous tumours in mice (Claes et al, 2008
accepted in Brain Pathology). On the day of intracerebral tumour
injection, a nude mouse carrying a subcutaneous E34 xenograft
was killed. The tumour was removed under sterile conditions and
minced to small pieces using a scalpel. A tumour cell suspension
was prepared by gently filtering the homogenate through a 70-mm
mesh filter. Twenty microlitres of this cell suspension was
transcranially injected, 3mm under the skull under standardised
conditions. The procedure was carried out with 7- to 8-week-old
Balb/c nude mice under anaesthesia with a mixture of 1.3%
isoflurane in N2O/O2. This procedure reproducibly results in
neurological symptoms due to intracerebral tumour growth 24–30
days after injection.
U87 glioma cells and stable VEGF-A165 transfectants of Mel57
cells were cultured in Dulbecco’s modified essential medium
supplemented with 10% fetal calf serum essentially as described
before (Kusters et al, 2002). For the U87 tumour model, 1 10
5
cells were injected transcranially using the same procedure as
described for E34. Mel57-VEGF-A165 cells were injected in the
internal carotid artery using a microsurgical procedure that was
described before (Kusters et al, 2001). Using this melanoma
metastasis model, multiple lesions develop in the brain paren-
chyma that display all hallmarks of angiogenesis (including leaky,
highly dilated vessels). All experiments were approved by the
Animal Experimental Committee of the Radboud University
Nijmegen.
Magnetic resonance imaging
Magnetic resonance imaging was performed as described in a
previous study (Leenders et al, 2003). Mice were anaesthesised
with isoflurane (1.5–2%) in N2O/O2; in each mouse, a catheter was
inserted in a lateral tail vein to allow administration of contrast
agent. A 10-mm diameter surface transmitter/receiver RF coil was
positioned over the mouse head. During the measurements, the
body temperature of the mice was maintained with a warm water
pad.
Magnetic resonance imaging experiments were performed on
a 7T/200mm horizontal-bore MR magnet interfaced to an
SMIS console and equipped with a gradient insert (gradient
strength¼150mTm
 1 and rise time¼150ms). The image acquisi-
tion protocol started with three gradient-echo scout images for
slice positioning. The protocol of the Gd-DTPA contrast-enhanced
MRI consisted of T1-weighted multislice gradient-echo images
with TR/TE¼400/6ms, voxel size¼136 136 1000mm, 16
slices, receiver bandwidth¼100kHz, scan time¼1min 16s. The
images were acquired prior to and 1, 2, 10 and 20min after
administration of Gd-DTPA (Magnevist
s; Schering, Berlin,
Germany) at a dose of 0.2mmolkg
 1.
A number of pilot experiments were performed to optimise the
protocol of blood volume measurements. At the dose of USPIO
agent used in the current study, a good compromise between
signal-to-noise ratio (SNR) and contrast enhancement was found
for values of TE in the range of 5–10ms. As susceptibility effects
scale linearly with the static magnetic field strength, longer
(shorter) values of TE might be advantageous for blood volume
measurements at a lower (higher) field. The protocol of the USPIO
contrast-enhanced MRI consisted of multislice gradient-echo
(TR/TE¼1500/7ms, 16 slices, voxel size¼136 136 1000mm,
receiver bandwith¼100kHz, scan time¼4min 54s) and
spin-echo (TR/TE¼2000/9ms, 16 slices, voxel size¼
136 136 1000mm, receiver bandwith¼100kHz, scan time-
6min 32s) imaging performed prior to and following administra-
tion of a USPIO blood-pool agent (Sinerem; Guerbet, Roissy,
France; 170mg Fe/mouse). Magnetic resonance imaging with
USPIO was performed 2–3h after Gd-DTPA imaging in mice with
intracerebral Mel57-VEGF-A165 (n¼4), E34 (n¼3) or U87 (n¼4)
tumours. This time gap allowed complete wash out of Gd-DTPA
and enabled a correlation between Gd-DTPA and USPIO
enhancement.
Data analysis
For each animal, pixel-by-pixel DR2* maps were obtained from the
formula DR2  ¼ð 1=TEÞlogðS
bef
o =S
aft
o Þ; where TE is the echo time,
and So the signal amplitude pre-USPIO (So
bef) and post-USPIO
(So
aft), in the gradient-echo images. The same algorithm was
employed to generate DR2 maps from the spin-echo images. For
each mouse, after DR2* and DR2 colormaps were generated, three
slices were chosen, based on the maximum values of DR2* in
tumours, as assessed on the DR2* colormaps. DR2* and DR2 were
measured in manually segmented ROIs on these slices. For each
animal carrying Mel57-VEGF-A165 tumours, at least five lesions
were analysed. In the animals carrying E34 and U87 tumours,
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smultiple ROIs (n¼9 per mouse) were defined within the tumour.
Similarly, ROIs were defined within healthy brain regions (in total,
nine ROIs in cortex and nine ROIs in striatum). For each ROI,
mean DR2 and DR2* were calculated by averaging the values of all
pixels within the ROI. For each tumour line, as well as for healthy
brain regions, the average and standard deviation was calculated
from all ROIs. All algorithms were implemented in Matlab
(Mathworks, Natick, MA, USA).
Histological and immunohistochemical analysis
After the MRI experiments, animals were killed and the brains
were removed and fixed in formalin. Coronal slices were
embedded in paraffin and processed for immunohistochemical
analysis. Vessels in E34, U87 and Mel57-VEGF-A165 lesions were
highlighted by staining for the endothelial marker CD34 (Hycult
Biotechnology, Uden, The Netherlands), glut-1 (Dakocytomation,
Glostrup, Denmark; a marker for brain vasculature) and the
pericyte marker a-smooth muscle actin (a-SM1; Sigma Chemical
Co., Zwijndrecht, The Netherlands) according to previously
published protocols (Kusters et al, 2002). To detect vascular perme-
ability in the different tumours, sections were stained with HRPO-
labelled anti-mouse IgG as described before (Kusters et al, 2002).
RESULTS
Precontrast MR images showed little or no contrast between
tumour and healthy brain tissue in all three tumour models
(Figures 1–3A and C). Following Gd-DTPA and USPIO adminis-
tration, tumours could be easily identified (Figures 1–3B and D).
Each tumour model displayed a distinctive pattern of vascular
morphology and enhancement following administration of con-
trast agents.
Following Gd-DTPA administration, all tumours were hyper-
intense indicating Gd-DTPA extravasation. This correlated well
with the vascular permeability in the tumours, as assessed by
anti-IgG staining (compare panels F in Figures 1–3). Following
administration of USPIO, the E34 glioma showed high values of
DR2 and DR2* throughout the tumour (Figure 1D and Table 1).
The Mel57-VEGF-A165 metastases appeared as black spots and
showed an expansive growth pattern (Figure 2D–F), with very
high values of DR2 and DR2* (Table 1). Interestingly, this
correlated well with the presence of highly dilated vessels (see
a-SM1 staining in Figure 2E). The U87 tumours were characterised
by a ring-like structure (Figure 3D), with relatively low DR2 and
DR2* values in the core and very high DR2 and DR2* values in the
peritumoral region. The values of DR2 and DR2* were also
measured in healthy brain regions (cortex: DR2¼5±2s
 1 and
DR2*¼21±9s
 1; striatum: DR2¼9±3s
 1 and DR2*¼
36±10s
 1). The macrovascular blood volume map of Mel57-
VEGF-A165 tumours is shown in Figure 4A. In Figure 4B, the
corresponding gradient-echo images are shown. A high threshold
for DR2* was used in the tumour areas (region inside the box).
Outside the tumour region, a low cutoff threshold for DR2* is used
to maximise the contrast between striatum (ROI indicated by the
horizontal arrow) and cortex (ROI indicated by the vertical arrow,
Figure 4B). For clarity, these two ROIs are drawn only on the
gradient-echo image.
DISCUSSION
The ability to noninvasively detect aberrant vasculature is
especially crucial for detection and delineation of brain tumours.
In this study, we demonstrate that MR-based imaging of blood
volume has important added value, as tumour vessels may be
dilated in the absence of notable hyperpermeability, and hence
may be better visualised by blood volume imaging. Specifically, in
addition to qualitative assessment of vascular volume, which can
be done by visually evaluating the change in signal intensity
following USPIO, a quantitative assessment of blood volume can
be performed by calculating DR2*. This allows for an objective
comparison of vascular volumes of different tumours and also
Pre-Gd-DTPA
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Figure 1 (A–D) Magnetic resonance images of mouse brain with a E34 glioma xenograft, acquired prior to (A and C) and following (B and D)
administration of Gd-DTPA (B, gradient-echo images, TR/TE¼400/6ms, in-plane resolution¼136 136mm) and USPIO (D, spin-echo images,
TR/TE¼2000/9ms, in-plane resolution¼136 136mm). In (B), the asteriscs (*) indicate the position of centre of the ROIs chosen for data analysis (see
also Table 1) and the white circle indicates the size of the ROIs. (E and F) Immunohistochemical staining for glut-1 highlighting vessels (E) and
immunostaining for extravasated mouse immunoglobulins (F). Note that vessel leakage is limited and heterogeneous. The arrow points at a tumour region
where IgG has extravasated. Such regional leakage is in agreement with the heterogeneity in Gd-DTPA extravasation as shown in (B). Note that the
Gd-DTPA-enhancing region underestimates the extent of the glioma in both hemispheres (compare B and D).
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sallows performance of longitudinal studies to assess, for example,
treatment efficacy. An important part in the MR assessment of
brain tumours in the clinic is the venous application of Gd-DTPA
to detect blood–brain barrier leakage due to hyperpermeable
tumour vessels. This results in interstitial Gd-DTPA accumulation,
which can be vizualised on T1-weighted images. However, as brain
tumours often show infiltrative growth without this leakage, no Gd-
DTPA enhancement on T1-weighted MRI is then observed. In these
cases, it is possible to use hyperintense lesions seen on T2-weighted
MRI without contrast agent to characterise the tumour extent, but as
oedema is also hyperintense on these images, tumour spread may be
overestimated, and also underestimation by T2-weighted MRI has
∗
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a
Pre-Gd-DTPA
Post-Gd-DTPA
Pre-USPIO A
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α-SM1 E
F IgG
Figure 2 (A–D) Magnetic resonance images of mouse brain with Mel57-VEGF-A165 tumour, acquired prior to (A and C) and following administration of
Gd-DTPA (B) and USPIO (D). The imaging parameters are the same as in Figure 1. From the image shown in the figure, three ROIs (labelled a, b and c)
were analysed. (E and F) Immunostainings for pericytes (E) and extravasated IgGs (F) of a lesion in a section matched with the MRI slice. Note the highly
dilatated tumour vasculature and the enormous amount of extravasated IgG.
Pre-Gd-DTPA
Post-Gd-DTPA
Pre-USPIO A
B Post-USPIO
C
D
E
IgG
Glut-1
F
Figure 3 (A–D) Magnetic resonance images of mouse brain with a U87 tumour, acquired prior to (A and C) and following administration of Gd-DTPA
(B) and USPIO (D), with the same imaging parameters as in Figure 1. (E and F) Immunohistochemical staining for glut-1 (E), highlighting vessels and an
immunostaining for extravasated mouse immunoglobulins (F) confirm the contrast-enhanced MRI findings of high tumour blood volume and vessel leakage.
Table 1 Mean and standard deviation of DR2 and DR2*
DR2* (s
 1) DR2( s
 1)
Mel57-VEGF-A165 284±89 40±13
E34 153±36 17±5
U87 (rim) 54±15 13±5
U87 (core) 17±65 ±3
Cortex 21±95 ±2
Striatum 36±10 9±3
ROI¼region of interest. Values of the mean and standard deviation of DR2a n dDR2*in
Mel57-VEGF-A165, E34 and U87 tumours and in healthy brain regions, averaged over all
(ROIs).
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sbeen reported (Pirzkall et al, 2001; Stadlbauer et al, 2004). In a few
studies, it has been shown that T2*-weighted MR imaging after
USPIO administration can have added value in the characterisation
of human Gd-enhancing tumours.
In all tumour models used in this study, little contrast between
healthy tissue and tumours was present in both T2- and T1-weighted
images, with the specific acquisition timing used to obtain these
images. Gadolinium-DTPA and USPIO contrast-enhanced MRI
allowed not only detection of the tumours but also a more detailed
characterisation of their vasculature. Overall, Mel57-VEGF-A165
tumours were characterised by higher blood volume than the E34
and U87 glioma xenografts. U87 tumours displayed higher blood
volumes in the tumour rim than in the core. Again, we were able to
confirm the MRI results with immunohistochemical stainings.
As Gd-DTPA and USPIO imaging were performed on the same
mice, we were able to spatially correlate enhancement patterns of
both contrast agents in the respective tumour models. It is well
established that vascular volume and vascular permeability are
among the best markers for in vivo tumour detection by MRI
(Dennie et al, 1998; Su et al, 1998; Le Duc et al, 1999; Tropres et al,
2001; Turetschek et al, 2001; Verhoye et al, 2002; Bremer et al,
2003; Pathak et al, 2003; Robinson et al, 2003; van Laarhoven et al,
2006). It is generally assumed that tumours trigger angiogenesis
or recruit blood vessels from the local vasculature, and, as a
consequence, have increased local blood volumes. However,
tumour cells may infiltrate healthy tissue and co-opt the pre-
existing vasculature, a situation of particular importance in brain
tumours (Kusters et al, 2002; Leenders et al, 2003). When this
phenomenon occurs in the absence of angiogenesis or vascular
alterations, this will result in a local decrease of blood volume,
relative to surrounding healthy tissue. We previously showed that,
upon USPIO administration, this decrease in blood volume
translates into hyperintense voxels as compared to the surrounding
tissue (Leenders et al, 2003). Thus, whether angiogenic or
infiltrative, tumours have blood volumes that are distinct from
the blood volume in adjacent normal tissue. These differences can
be detected using blood-pool contrast agents such as USPIOs. Also,
in light of our previous studies that showed that anti-VEGF
treatment of brain tumours resulted in undetectability using Gd-
DTPA MR imaging (due to restoration of the blood–brain barrier
(Leenders et al, 2004; Claes et al, 2008)), USPIO imaging may be an
attractive avenue to delineate brain tumours and evaluate
antiangiogenic therapy.
For blood volume assessment of the macrovasculature and
microvasculature, T2*-weighted gradient-echo and T2-weighted
spin-echo images, respectively, need to be acquired prior to and
following administration of USPIO. As shown in this study, the
vascular morphology of the tumour is best visualised on post-
USPIO gradient-echo images. Due to its high transverse relaxivity
(B100mM
 1s
 1, at 7T (Gambarota et al, 2006)), USPIO provides
an extremely high sensitivity to alterations in local tissue blood
volume; as a result, it generates a high signal contrast in
T2*-weighted images between regions of different blood volume.
With respect to DR2, for typical USPIO concentrations employed
in in vivo studies, only minor signal dephasing (and thus small
DR2) originates in spin-echo images following USPIO administra-
tion (Le Duc et al, 1999; Gambarota et al, 2006). On the other hand,
DR2 changes are sensitive to the small vasculature network,
and therefore DR2 could be exploited for characterisation of the
tumour microvasculature (Kennan et al, 1994; Weisskoff et al,
1994; Dennie et al, 1998; Le Duc et al, 1999). However, to detect
USPIO-induced signal dephasing in spin-echo acquisitions, long
echo times (B100ms) need to be employed, at the expense of the
image SNR.
In the current study, all tumour models displayed vessel leakage,
albeit at different degrees. Leakage of Gd-DTPA from tumour
vessels into the interstitium is however not restricted to the
tumour interstitium but can extent into the surrounding normal
tissue. This obviously precludes an accurate estimation of tumour
edges. As tumour (and edge) detection rely on factors that include
(i) the signal intensity contrast between the lesion and peritumoral,
non-neoplastic tissue and (ii) the spatial resolution of the MR
image, USPIO (R2 relaxivity B100mM
 1s
 1) has the advantage
over Gd-DTPA (R1 relaxivity B5m M
 1s
 1) of potentially
improving both (i) and (ii).
In conclusion, detailed characterisation of the tumour
vasculature by imaging vascular leakage and vascular volume
provides a better understanding of the complex mechanisms
associated with tumour development. Gadolinium-DTPA and
USPIO contrast-enhanced MRI allow not only the detection of
tumours but also characterisation of their vasculature, which is
essential for diagnostic purposes and to assess efficacy of, for
example, antiangiogenic therapy. Tumours from the three tumour
models displayed three distinctive vascular morphologies, which
were best assessed on post-USPIO gradient-echo images. The
results of this study indicate that USPIO-induced DR2* values are
highly sensitive to small changes in regional blood volume. Thus
USPIO imaging may be a very attractive alternative to Gd-DTPA
imaging and will at least have added value, especially for detection
and delineation of diffuse infiltrative brain tumours.
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